Background: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths.
Methods: This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020. Provisional data regarding numbers accessing treatment for opioid use disorder was provided by the National Drug Treatment Monitoring System.
Results: We found a 64% increase in methadone-related deaths in March to June 2020 compared to March to June 2019 (2019 n = 96; 2020 projected n = 157). There were increases in the mortality rate of both in-treatment decedents (22% increase; 2019 n = 45; an exponential smoothing model of the 2016-19 trend [α=0.5] predicted 44 deaths in 2020, 55 were reported) and decedents not prescribed methadone (74% increase; 2019 n = 46; 2016-19 trend predicted 43 deaths in 2020, 80 were reported). There was no increase in buprenorphine-related deaths (2019 n = 9/529; 2020 n = 11/566). There were no changes in the numbers of deaths where other opioids or multiple substances were detected, or in methadone levels detected. Numbers of people accessing treatment for opioid use disorder in 2020 did not decrease relative to previous years (p >0.05).
Conclusions: Methadone-related deaths in non-prescribed individuals, but not prescribed individuals, increased considerably above the annual trend forecast for 2020 during the first COVID-19 lockdown in England. Further studies are thus needed to understand this difference.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531664 | PMC |
| http://dx.doi.org/10.1016/j.drugpo.2022.103877 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Community pharmacy-based buprenorphine programs and pharmacists' roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: A systematic review.
J Am Pharm Assoc (2003)
December 2024
Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA.
Background: Buprenorphine is an effective medication for treating opioid use disorder (OUD) and reducing opioid-related overdose deaths. Community pharmacies are key access points for buprenorphine, with pharmacists well-positioned to dispense and counsel patients on appropriate use. Recent evidence has identified pharmacists' growing engagement in buprenorphine services; yet, access to buprenorphine and related services in community pharmacies remains limited.
View Article and Find Full Text PDFBuprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland.
Int J Legal Med
November 2024
Department of Forensic Medicine, University of Helsinki, P.O. Box 21(Haartmaninkatu 3), Helsinki, 00014, Finland.
Article Synopsis
- The study analyzed opioid agonist treatment (OAT) status before buprenorphine-related deaths in Finland from 2018 to 2020, revealing that only 10% of the deceased had received OAT in the year prior.
- Less than 1% of individuals under 25 had received OAT, compared to 13% of those 25 and older, with higher rates of female deaths and fatal poisonings among the younger group.
- Although receiving OAT resulted in fewer benzodiazepine findings, substance misuse, especially of benzodiazepines and other drugs, was common across both OAT and non-OAT individuals, indicating a need for improved access to OAT and treatment for multiple addictions, particularly for younger adults
Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.
Int J Drug Policy
December 2022
South London and Maudsley NHS Foundation Trust, London, United Kingdom; National Addictions Centre, Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, United Kingdom. Electronic address:
Background: The coronavirus pandemic resulted in many changes which had the potential to impact mortality related to opioid agonist therapy (OAT; methadone, buprenorphine), including changes in the prescribing and dispensing of OAT and patterns of drug availability and use. We aimed to assess the impact of the first lockdown (initiated March 23rd 2020) on methadone- and buprenorphine-related deaths in England in people both prescribed and not prescribed OAT using data from the National Programme on Substance Abuse Deaths.
Methods: This was a retrospective post-mortem toxicology study of OAT-related deaths which occurred in the 3-month period March 23rd to June 22nd in the years 2016-2020.
Investigation of buprenorphine-related deaths using urinary metabolite concentrations.
Drug Test Anal
October 2022
Department of Forensic Medicine, University of Helsinki, Helsinki, Finland.
Quantitative analysis of postmortem urine, instead of blood, for buprenorphine and metabolites may provide additional evidence for the diagnosis of fatal buprenorphine poisoning. In this study, 247 autopsy urine samples, previously testing positive for buprenorphine or norbuprenorphine, were quantitatively reanalysed with a recently developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for unconjugated buprenorphine (BUP), norbuprenorphine (NBUP), naloxone (NAL), and their respective conjugated metabolites, buprenorphine glucuronide (BUPG), norbuprenorphine glucuronide (NBUPG), and naloxone glucuronide (NALG). The cases were divided, according to medical examiners' decision, to buprenorphine poisonings and other causes of death.
View Article and Find Full Text PDFBuprenorphine-Related Deaths in North Carolina from 2010 to 2018.
J Anal Toxicol
September 2021
Office of the Chief Medical Examiner, 4312 District Dr, Raleigh, NC 27607, USA.
Buprenorphine (BUP) is a commonly prescribed medication for the treatment of opioid use disorder (OUD). As prescriptions increase in North Carolina, BUP is more frequently encountered statewide in routine postmortem casework. Between 2010 and 2018, there were 131 select cases investigated by the Office of the Chief Medical Examiner where BUP was detected in peripheral blood and considered a primary cause of death (COD), with no other opioids present and no other non-opioid substances found in the lethal range.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!